Business Wire

SFL - Third-Quarter 2019 Financial Information

14.10.2019 20:21:00 EEST | Business Wire | Press release

Share

Regulatory News:

SFL (Paris:FLY):

Consolidated revenue by business segment (€000’s)

 

 

 

2019
(9 months)

2018
(9 months)

Rental income

149,070

143,790

o/w

Paris Central Business District

121,877

119,038

 

Paris Other

25,786

22,479

 

Western Crescent

1,407

2,273

Other revenue

0

0

Total consolidated revenue

149,070

143,790

Consolidated rental income for the first nine months of 2019 amounted to €149.1 million, up €5.3 million or 3.7% from the €143.8 million reported for the same period of 2018.

- On a like-for-like basis (excluding all changes in the portfolio affecting period-on-period comparisons), rental income was €4.8 million (3.5%) higher, attributable to new leases signed in 2018, mainly in the Cézanne Saint-Honoré, Washington Plaza, #cloud.paris and 103 Grenelle properties, and to index increases.

- Rental income from spaces being redeveloped declined by €2.4 million over the period, mainly reflecting the departure in 2018 of the last tenants from the 83 Marceau building, which is currently being renovated, and the refurbishment of several floors in the 176 Charles de Gaulle building in Neuilly that were vacated at the end of last year.

- Lastly, income from various penalties was up by €2.9 million, mainly due to the early termination of a lease at 103 Grenelle during the course of the third quarter.

During the first nine months of 2019, SFL signed leases for around 31,000 sq.m. on excellent terms, including nearly 7,000 sq.m. in the third quarter, mainly at 112 Wagram and 103 Grenelle in Paris, and 176 Charles de Gaulle in Neuilly. The new leases were signed at an average nominal rent of €752 per sq.m., corresponding to an effective rent of €654 per sq.m.

At 30 September 2019, the physical occupancy rate for revenue-generating properties remained very high at 97.4%, compared with 97.3% at 31 December 2018, while the EPRA vacancy rate came to 1.8%, versus 1.6% at year-end 2018.

No properties were purchased or sold during the first nine months of 2019.

SFL’s consolidated net debt at 30 September 2019 amounted to €1,734 million, compared with €1,688 million at 31 December 2018, representing a loan-to-value ratio of 23.8% based on the portfolio’s appraisal value at 30 June 2019. The average cost of debt after hedging was 1.4% and the average maturity was 4.0 years. At end-September 2019, the interest coverage ratio stood at 6.4x.

In addition, SFL had €990 million in undrawn lines of credit at 30 September 2019.

About SFL

Leader in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €6.8 billion and is focused on the Central Business District of Paris (#cloud.paris, Edouard VII, Washington Plaza, etc.), and for the quality of its client portfolio, which is composed of prestigious companies in the consulting, media, digital, luxury, finance and insurance sectors. As France’s oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties.

Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA

S&P rating: BBB+ stable outlook

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

SFL - Thomas Fareng - Phone +33 (0)1 42 97 27 00 - t.fareng@fonciere-lyonnaise.com
Evidence - Grégoire Silly - Phone: 06 99 10 78 99 - gregoire.silly@evidenceparis.fr

www.fonciere-lyonnaise.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye